Fig. 4

Fasn is a substrate for CMA. (A) The protein expression level of Fasn in WT cells treated with or without the 5 mM lysosomal inhibitor NH₄Cl for 24 h (n = 4 independent experiments). (B) The protein expression levels of Fasn (n = 3 independent experiments) in WT cells treated with or without 500 nM Wortmannin for 24 h. (C) The protein expression levels of Fasn (n = 5 independent experiments) and Plin2 (n = 3 independent experiments) in KO cells treated with or without 20 μM AR7 for 24 h. (D) KFERQ-like motif prediction of mouse Fasn and human FASN. (E) The interaction between Fasn and HSC70 was analyzed by Co-IP. The data are expressed as the mean ± SD; *p < 0.05, ** p < 0.01, *** p < 0.001